A Case of Bladder Cancer in a Patient with Systemic Lupus Erythematosus Treated with Oral Cyclophosphamide / 대한류마티스학회지
The Journal of the Korean Rheumatism Association
;
: 286-291, 2004.
Artículo
en Coreano
| WPRIM
| ID: wpr-49117
ABSTRACT
Cyclophosphamide, a cytotoxic alkylating agent, is widely used in various benign diseases like systemic lupus erythematosus (SLE), Wegener's granulomatosis, rheumatoid arthritis, nephrotic syndrome as well as in malignancies and organ transplantation. Cyclophosphamide is metabolized in the liver to various chlormethine metabolites and acrolein, which mediates the toxic effect to the urothelium and can cause hemorrhagic cystitis, bladder fibrosis, and has also been associated with urothelial malignancies including bladder cancer. It is known that SLE is not associated with an increased risk for the development of most of the solid tumors. But it has been suggested that the risk of the bladder cancer increases in patients with benign diseases such as SLE treated by cyclophosphamide. There are only very few reports of cyclophosphamide-induced bladder cancer in SLE so far. We report a case of a patient who developed bladder cancer 13 years after cyclophosphamide was given as therapy for SLE. This case shows that careful observation and urologic evaluation is undoubtedly important for patients treated with cyclophosphamide.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Artritis Reumatoide
/
Vejiga Urinaria
/
Acroleína
/
Neoplasias de la Vejiga Urinaria
/
Fibrosis
/
Granulomatosis con Poliangitis
/
Trasplante de Órganos
/
Urotelio
/
Trasplantes
/
Ciclofosfamida
Límite:
Humanos
Idioma:
Coreano
Revista:
The Journal of the Korean Rheumatism Association
Año:
2004
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS